论文部分内容阅读
目的:观察依达拉奉联合尤瑞克林治疗急性脑梗塞的疗效及安全性。方法:将84例急性脑梗塞患者随机分为2组,对照组予依达拉奉30 mg加入生理盐水100 mL静脉滴注,每日两次。观察组在上述基础上另予尤瑞克林0.15 PNA加入生理盐水250mL中静脉滴注,每天一次。两组疗程均为2周。观察两组患者的神经功能缺损评分、疗效与不良反应。结果:两组患者神经功能缺损评分均较治疗前明显改善(P<0.01),观察组评分明显低于对照组(P<0.01)。观察组临床总有效率达97.6%,明显高于对照组的57.1%(P<0.01)。两组不良反应发生率无统计学差异。结论:达拉奉联合尤瑞克林治疗急性脑梗塞临床疗效好,安全性高。
Objective: To observe the efficacy and safety of edaravone combined with noreclin in the treatment of acute cerebral infarction. Methods: Eighty-four patients with acute cerebral infarction were randomly divided into two groups. The control group was given edaravone 30 mg intravenously with 100 mL normal saline twice a day. On the basis of the above, the observation group was additionally given intravenous injection of uracil 0.15 PNA into 250 mL normal saline once a day. Two groups of treatment are 2 weeks. The neurological deficit scores, curative effects and adverse reactions of the two groups were observed. Results: The scores of neurological deficit in both groups were significantly improved (P <0.01), and the scores in the observation group were significantly lower than those in the control group (P <0.01). The total effective rate in the observation group was 97.6%, which was significantly higher than that in the control group (57.1%, P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: The combination of dalarmon and uricin in the treatment of acute cerebral infarction has good curative effect and high safety.